BLUE [NASD]
bluebird bio, Inc.
Index- P/E- EPS (ttm)-8.01 Insider Own1.50% Shs Outstand73.69M Perf Week-3.27%
Market Cap287.73M Forward P/E- EPS next Y-2.42 Insider Trans-2.55% Shs Float70.62M Perf Month31.01%
Income-563.30M PEG- EPS next Q-1.24 Inst Own89.80% Short Float17.84% Perf Quarter-16.19%
Sales4.70M P/S61.22 EPS this Y9.50% Inst Trans6.70% Short Ratio2.06 Perf Half Y-62.16%
Book/sh3.57 P/B1.16 EPS next Y44.80% ROA- Target Price7.33 Perf Year-79.48%
Cash/sh3.04 P/C1.36 EPS next 5Y- ROE- 52W Range2.87 - 21.16 Perf YTD-58.56%
Dividend- P/FCF- EPS past 5Y-2.90% ROI-157.90% 52W High-79.77% Beta1.33
Dividend %- Quick Ratio- Sales past 5Y-9.90% Gross Margin- 52W Low49.39% ATR0.55
Employees518 Current Ratio1.80 Sales Q/Q111.10% Oper. Margin- RSI (14)55.25 Volatility11.63% 16.02%
OptionableYes Debt/Eq0.00 EPS Q/Q8.60% Profit Margin- Rel Volume0.65 Prev Close4.14
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout- Avg Volume6.11M Price4.28
Recom3.20 SMA2014.09% SMA5015.89% SMA200-45.25% Volume3,986,338 Change3.38%
Apr-06-22Downgrade Cowen Outperform → Market Perform
Mar-07-22Downgrade Barclays Equal Weight → Underweight $4
Nov-08-21Reiterated Wells Fargo Equal Weight $25 → $16
Nov-08-21Reiterated Wedbush Neutral $22 → $11
Nov-08-21Reiterated RBC Capital Mkts Sector Perform $26 → $14
Nov-08-21Reiterated Canaccord Genuity Hold $20 → $15
Nov-08-21Reiterated Barclays Equal Weight $20 → $13
Nov-08-21Downgrade Morgan Stanley Equal-Weight → Underweight $11
Nov-08-21Downgrade Goldman Neutral → Sell $23 → $10
Aug-10-21Resumed William Blair Mkt Perform
Aug-10-21Downgrade Wells Fargo Overweight → Equal Weight $60 → $25
Aug-10-21Downgrade Goldman Buy → Neutral $63 → $23
Aug-10-21Downgrade Canaccord Genuity Buy → Hold
Aug-09-21Downgrade SVB Leerink Outperform → Mkt Perform
Jul-01-21Downgrade Berenberg Buy → Hold $35
Mar-10-21Upgrade Mizuho Neutral → Buy $34 → $69
Feb-17-21Downgrade JP Morgan Overweight → Neutral $76 → $39
Feb-16-21Downgrade William Blair Outperform → Mkt Perform
Feb-16-21Downgrade Wedbush Outperform → Neutral
Feb-16-21Downgrade BofA Securities Buy → Neutral
Jun-23-22 11:30AM  
Jun-18-22 10:15AM  
Jun-17-22 12:03PM  
Jun-14-22 01:55PM  
Jun-13-22 02:25PM  
01:27PM  
01:27PM  
12:50PM  
08:20AM  
07:54AM  
06:48AM  
Jun-10-22 03:42PM  
03:30PM  
03:18PM  
01:03PM  
08:29AM  
Jun-09-22 08:21PM  
06:17PM  
06:14PM  
07:29AM  
07:05AM  
Jun-08-22 01:21PM  
11:30AM  
Jun-07-22 01:32PM  
08:36AM  
May-19-22 06:00PM  
May-13-22 10:32AM  
May-09-22 06:25PM  
04:05PM  
Apr-27-22 03:03PM  
Apr-22-22 03:29PM  
Apr-17-22 11:15AM  
Apr-15-22 11:30AM  
Apr-08-22 06:57AM  
Apr-06-22 12:36PM  
Apr-05-22 12:14PM  
08:59AM  
07:21AM  
07:00AM  
Mar-29-22 07:00AM  
Mar-24-22 07:00AM  
Mar-23-22 02:41PM  
Mar-10-22 05:01PM  
Mar-07-22 02:58PM  
12:00PM  
Mar-04-22 05:45PM  
04:31PM  
Feb-28-22 05:45PM  
Feb-17-22 10:52AM  
Feb-15-22 03:01PM  
Feb-01-22 09:38PM  
Jan-26-22 08:00AM  
Jan-20-22 05:36AM  
Jan-19-22 11:29AM  
Jan-18-22 07:00AM  
Jan-14-22 08:37AM  
Jan-13-22 05:45AM  
Jan-11-22 12:11PM  
07:00AM  
Jan-05-22 08:00AM  
Jan-04-22 03:33PM  
Dec-23-21 06:35AM  
Dec-20-21 11:15AM  
09:13AM  
08:38AM  
08:10AM  
08:00AM  
Dec-17-21 06:35PM  
Dec-15-21 10:00AM  
Dec-12-21 05:04PM  
Dec-11-21 10:33AM  
Dec-09-21 07:38PM  
Nov-22-21 06:54AM  
06:30AM  
Nov-17-21 02:33PM  
Nov-12-21 10:50AM  
Nov-08-21 05:30PM  
Nov-07-21 07:12AM  
Nov-05-21 08:25AM  
07:05AM  
07:00AM  
06:58AM  
Nov-04-21 04:35PM  
09:00AM  
07:00AM  
Oct-27-21 03:04PM  
Oct-25-21 02:44PM  
Oct-21-21 09:59AM  
Oct-18-21 09:00AM  
Oct-08-21 04:54PM  
Sep-22-21 07:03AM  
Sep-21-21 04:15PM  
Sep-13-21 08:00AM  
Sep-08-21 11:30AM  
07:30AM  
Sep-07-21 04:05PM  
Aug-13-21 10:50PM  
Aug-11-21 01:22AM  
Aug-09-21 04:04PM  
12:38PM  
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klima Thomas JChief Commercial OfficerJun 03Sale3.073,75311,53571,439Jun 07 04:16 PM
Cole JasonChief Operating andJan 11Sale9.643,38732,659186,188Jan 12 09:15 PM
Leschly NickDirectorJan 11Sale9.645,06848,869281,330Jan 12 09:15 PM
Obenshain AndrewPresident and CEOJan 11Sale9.644,68345,156246,696Jan 12 09:15 PM
Whitten JessicaChief Accounting OfficerJan 11Sale9.642792,69049,413Jan 12 09:16 PM
Whitten JessicaChief Accounting OfficerJan 10Sale9.401301,22249,692Jan 12 09:16 PM
Obenshain AndrewPresident and CEOJan 10Sale9.363,04228,467251,379Jan 12 09:15 PM
Leschly NickDirectorJan 10Sale9.402,36922,274286,398Jan 12 09:15 PM
Cole JasonChief Operating andJan 10Sale9.401,58414,893189,575Jan 12 09:15 PM
Whitten JessicaChief Accounting OfficerJan 05Sale10.442,98431,14349,822Jan 07 04:28 PM
Obenshain AndrewPresident and CEODec 07Sale10.188328,469254,421Dec 09 04:51 PM